Project Grant R01DA058438

Award Date 5/1/24
Completion Date 2/28/30
Dollars Obligated $939K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This federal Project Grant award of $695,250, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at Howard University examining the role of endothelial injury and myeloid cell migration in the activation of inflammasomes in HIV infection and cocaine exposure. The research aims to characterize myeloid cell populations in the brains of HIV-transgenic mice under chronic cocaine treatment, evaluating the number,...
The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1,372,480 Project Grant to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC). The grant supports a 5-year research study focused on elucidating the molecular mechanisms underlying the interplay between HIV transactivator of transcription (Tat) protein, cocaine, and combination antiretroviral therapy (cART) in activating the...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,475,580 to The Regents of the University of California, San Francisco (UCSF) to conduct in-depth spatial characterization of HIV-host cellular interactions within the central nervous system (CNS) of people living with HIV (PWH) who died suddenly. The key objectives are to: (1) implement innovative spatial multi-omic assays to analyze the...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,481,760 to Emory University to study how methamphetamine (MA) use impacts immune dysfunction in people living with HIV (PWH) on antiretroviral therapy (ART). The 5-year award will leverage existing longitudinal blood samples and collect new blood and cerebrospinal fluid samples to investigate a multi-step process by which MA promotes...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,940,518 to Wake Forest University Health Sciences (WFUHS) to conduct a randomized controlled trial (RCT) investigating neuroimmune mechanisms linking psychosocial stress, stimulant use, and depression in people living with HIV (PWH). The study aims to (1) examine the impact of a positive affect intervention (ARTEMIS) on neural...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $162,486 to The Medical College of Wisconsin, Inc. to study the effects of concurrent chronic stress and cocaine self-administration on medial prefrontal cortex (mPFC) microglia and drug choice behavior in a rat model. The key objectives are to: Use flow cytometry, qRT-PCR, and spine morphometry to investigate microglial activity profiles and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This four-year, $4.6 million project grant from the National Institute on Drug Abuse will fund research at the University of Miami exploring the linkage between cannabis use, route of administration, cannabinoid content, and measures of cardiovascular disease (CVD) risk in people living with HIV (PWH). Specifically, the principal investigator - an interventional cardiologist and physician scientist focused on HIV and CVD prevention - will collect comprehensive data on 300 PWH ages 18-60 to...

COCAINE ABSTINENCE OR REDUCED USE MAY RETARD ALTERATIONS IN BRAIN STRUCTURE AND FUNCTION, AND ASSOCIATED COGNITIVE CHANGES AMONG AFRICAN AMERICAN COCAINE USERS WITH HIV - ABSTRACT DESPITE THE USE OF EFFECTIVE ANTIRETROVIRAL THERAPY (ART), HIV-RELATED NEUROCOGNITIVE IMPAIRMENT (NCI) CONTINUES TO BE PREVALENT AMONG PEOPLE LIVING WITH HIV. FOR MORE THAN 20 YEARS, OUR INVESTIGATION OF HIV- ASSOCIATED COMORBIDITIES AMONG AFRICAN AMERICANS (AAS) HAS DEMONSTRATED THAT WHILE COMORBIDITIES ARE PREVALENT AMONG AAS LIVING WITH HIV, OTHER FACTORS, SUCH AS COCAINE USE, MAY TRIGGER OR ACCELERATE THEIR IMPACT. WE HAVE SHOWN THAT ALTHOUGH HIV INCREASES THE RISK OF CORONARY PLAQUE, THE DETRIMENTAL EFFECT OF HIV/ART PREDOMINANTLY AFFECTS COCAINE USERS RATHER THAN NON-USERS. LIKEWISE, OUR PRELIMINARY WORK SHOWED THAT WHILE HIV WAS ASSOCIATED WITH NCI, THE ADVERSE EFFECT OF HIV PRIMARILY IMPACTED COCAINE USERS. FURTHERMORE, OUR ONGOING HEART STUDY SHOWED THAT A CONTINGENCY MANAGEMENT (CM) INTERVENTION IS EFFECTIVE IN ACHIEVING A SUSTAINED REDUCTION IN COCAINE USE AMONG AA COCAINE USERS WITH SUBCLINICAL HEART DISEASE AND WAS ASSOCIATED WITH A CONCURRENT DECREASE IN CORONARY PLAQUE BURDEN. COCAINE USE AND NCI CONTINUE TO DISPROPORTIONATELY AFFECT AAS, ESPECIALLY THOSE LIVING WITH HIV. AS OF NOW, THERE ARE NO FDA-APPROVED MEDICATIONS FOR COCAINE ADDICTION. WE PROPOSE TO INVESTIGATE WHETHER CM CAN BE EMPLOYED TO DECREASE COCAINE USE AND SLOW COGNITIVE DECLINE AMONG AA COCAINE USERS. THERE IS NO SINGLE DEFINITIVE BIOMARKER THAT CAN MEASURE COGNITIVE DECLINE; HOWEVER, BRAIN MRI MAY DETECT EARLY STRUCTURAL CHANGES IN THE BRAIN THAT SIGNIFY COGNITIVE DECLINE, PRIOR TO THE ONSET OF SYMPTOMS. OUR LATEST BRAIN MRI STUDY REVEALED AN INDEPENDENT ASSOCIATION BETWEEN COCAINE USE AND THE LENGTH OF ITS USE WITH AN INCREASED SEVERITY OF WHITE MATTER HYPERINTENSITIES (WMH) AND A DECREASE IN HIPPOCAMPAL (HP) VOLUME AMONG AAS. WMH ARE RECOGNIZED AS ONE OF THE MOST PROMISING BRAIN MRI MARKERS OF COGNITIVE DECLINE ALONG WITH HP VOLUME. THUS, WE PROPOSE A 5-YEAR STUDY TO EVALUATE THE EFFECTS OF A 12-MONTH CM INTERVENTION ON THE BRAIN MRI BIOMARKERS AND COGNITIVE PERFORMANCE ASSESSED WITH NIH TOOLBOX COGNITION BATTERY (NIHTB-CB) AMONG AA COCAINE USERS. WE WILL RECRUIT 180 AA COCAINE USERS, 40 YEARS OF AGE, INCLUDING AN EQUAL NUMBER OF MEN AND WOMEN WITH AND WITHOUT HIV, DRAWN FROM OUR ONGOING STUDY (U01DA040325). PARTICIPANTS WILL UNDERGO A 12-MONTH CM TO REINFORCE COCAINE ABSTINENCE WITH AN ESCALATING CASH INCENTIVE APPROACH. IN AIM 1, WE WILL EVALUATE THE EFFECTS OF A 12-MONTH CM ON MRI MEASURES OF BRAIN STRUCTURE AND FUNCTION (WMH, HP VOLUME, RESTING STATE FMRI AND OTHER MEASURES) AND COGNITIVE PERFORMANCE (NIHTB-CB). IN AIM 2, WE WILL EVALUATE THE NET EFFECT OF HIV ON BRAIN MRI MEASURES AND COGNITIVE PERFORMANCE. IN AIM 3, WE WILL STUDY WHETHER CHANGES IN BRAIN MRI MEASURES DURING THE 12- MONTH CM PERIOD ARE ASSOCIATED WITH CHANGES IN COGNITIVE PERFORMANCE. THIS STUDY WILL ESTABLISH THE EFFECTIVENESS OF A TARGETED INTERVENTION IN REDUCING COCAINE USE AND IMPROVING COGNITIVE OUTCOMES IN AA COCAINE USERS LIVING WITH HIV, THEREBY ADDRESSING A RECOGNIZED HEALTH DISPARITY IN THE AA POPULATION.

Posted 4/19/24